Table 5 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy complication, using other assays

 Auer et al. 2014 [173]

3-color FISH

1. BC cases (67)

2. Healthy controls (62)

Lymphocyte

2 Gy

Spontaneous RS

BC cases ↔ Healthy controls

RS after radiation

BC cases > Healthy controls

 Barwell et al. 2007 [174]

Terminal restriction fragment length assay

1. BC cases (212)

2. Healthy controls (1804)

WBC & lymphocyte

1. caesium-137 source at 0.5/1 Gy, or mock

2. caesium-137 source at 4 Gy, or mock

RS after radiation

BC cases ↔ Healthy controls

 West et al. 1995 [172]

Colony formation

1. BC cases with acute complication (7)

2. BC cases with late complication (6)

3. BC cases W/O complication (8)

4. Healthy controls (20)

Lymphocyte

HDR:

1.55 Gy min^-1

LDR:

0.0098 Gy min^-1

HDR

RS after radiation

BC cases ↔ Healthy controls

LDR

RS after radiation

BC cases ↔ Healthy controls

 Oppitz et al. 2002 [158]

Colony formation

1. BC cases with elevated acute reactions (6)

2. BC cases with average acute reactions (17)

Fibroblast

5 Gy

Spontaneous RS

Elevated acute reactions ↔ Average acute reactions

Radiosensitivity after radiation

Elevated acute reactions ↔ Average acute reactions

 West et al. 1995 [172]

Colony formation

1. BC cases with acute complication (7)

2. BC cases with late complication (6)

3. BC cases without complication (8)

4. Healthy controls (20)

Lymphocyte

HDR:

1.55 Gy min^-1

LDR:

0.0098 Gy min^-1

HDR

RS after radiation

BC with acute/late complication ↔ Healthy controls

BC W/O complication ↔ Healthy controls

LDR

RS after radiation

BC with acute/late complication > Healthy controls

BC cases W/O complication ↔ Healthy controls